Prexasertib mesylate (also known as LY2606368 mesylate) is a novel, potent, selective and ATP competitive inhibitor of the CHK1 (checkpoint kinase 1) protein kinase with potential anticancer activity.

Olomoucine, a purine derivative, is a novel and potent CDK (cyclin-dependent kinases) inhibitor that competes for the ATP binding site of the kinase and induces G arrest.

JSH-150 is a potent CDK9 inhibitor.

PHA-793887 (PHA793887; PHA 793887) is a novel and ATP-competitive inhibitor of the multi-CDK (cyclin dependent kinases) for CDK2, CDK5 and CDK7 with potential anticancer activity.

NVP-LCQ195 (formerly also known as AT9311; AT-9311; LCQ195; LCQ-195) is a novel and potent small molecule heterocyclic inhibitor of cyclin-dependent kinases CDK1, CDK2, CDK3 and CDK5 with IC50 of 1-42 nM.

ARS-853 is a novel, potent, selective, and covalent inhibitor of KRAS(G12C) with IC50 of 2.5 μM.

Palbociclib HCl (Pfizer trade name Ibrance, also known as PD-0332991), the HCl salt of Palbociclib, is a highly selective, orally bioavailable pyridopyrimidine-derived inhibitor of CDK4/6 with potential antineoplastic activity.

Roniciclib (formerly also known as BAY1000394; BAY-1000394) is a novel, potent and orally bioavailable pan-cyclin dependent kinase (CDK) inhibitor wwith anticancer activity.

SU 9516 (SU-9516; SU9516), a 3-substituted indolinone, is a potent and selective Cyclin-dependent kinases (CDKs) inhibitor with potential antineoplastic activity.

Mevociclib (formerly SY-1365; SY1365) is a novel, potent, highly selective and covalent/irreversible inhibitor of CDK7 (Cyclin-dependent kinase 7) with anticancer activity.